Health

Results: 9841-9852 of 10111

Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Illustrative example: cancer associated fibroblasts (CAFs) and the tumor microenvironment. (Photo: Business Wire)

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

PR Newswire associated0

EVERSANA Expands Global Commercialisation Capabilities and Strengthens Agency Network with Healthware Group Acquisition

Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis

PR Newswire associated0

KHB Becomes First Chinese Company to Obtain EU Class D IVDR Certification for Its Rapid Test HIV Colloidal Gold Diagnostic Kit

PR Newswire associated0

Clarivate Healthcare Business Insights Announces 2022 Revenue Cycle Awards Recipients

Nick Cooke, consultant in trauma and orthopaedics at North Tees and Hartlepool NHS Foundation Trust, wears a RealWear healthcare wearable solution to accommodate a diverse group of students, including those training to be paramedics, radiographers and physiotherapists. (Photo: Business Wire)

RealWear Offers Students Bird’s-Eye View of Orthopaedic Surgical Procedures in Operating Theatres at North Tees and Hartlepool NHS Foundation Trust

Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids

InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE